Enliven Therapeutics Inc
ELVNHealthcare|Biotechnology|USA
$51.09
-1.09 (-2.09%)
Tangible Book
$7.45
Clinical Trials (4)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05650879 ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer | HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer | P1 | Active | 198 | Open-label | ELVN-002, Fam-Trastuzumab Deruxtecan-Nxki, Trastuzumab emtansine |
| NCT05304377 A Phase 1a/1b Study of ELVN-001 for the Treatment Chronic Myeloid Leukemia | Chronic Myeloid Leukemia, Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | P1 | Recruiting | 250 | Open-label | ELVN-001 |
| NCT06787144 ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants | CML (Chronic Myelogenous Leukemia), Chronic Phase CML | P1 | Recruiting | 21 | Open-label | ELVN-001 |
| NCT06328738 ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer | HER2-positive Breast Cancer, HER2-positive Gastric Cancer | P1 | Active | 275 | Open-label | ELVN-002, Trastuzumab, 5-Fluorouracil, Oxaliplatin, Capecitabine, Eribulin, paclitaxel, Leucovorin |